Generic Detrol LA Availability

See also: Generic Detrol

Detrol LA is a brand name of tolterodine, approved by the FDA in the following formulation(s):

DETROL LA (tolterodine tartrate - capsule, extended release;oral)

  • Manufacturer: PHARMACIA AND UPJOHN
    Approval date: December 22, 2000
    Strength(s): 2MG [AB], 4MG [RLD] [AB]

Has a generic version of Detrol LA been approved?

A generic version of Detrol LA has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Detrol LA and have been approved by the FDA:

tolterodine tartrate capsule, extended release;oral

  • Manufacturer: MYLAN PHARMS INC
    Approval date: October 31, 2013
    Strength(s): 2MG [AB], 4MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Detrol LA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical formulation and its use
    Patent 6,630,162
    Issued: October 7, 2003
    Inventor(s): Lisbeth; Nilvebrant & Bengt; Hallen & Birgitta; Olsson & Jan; Strombom & Torkek; Gren & Anders; Ringberg & Martin; Wikberg
    Assignee(s): Pharmacia AB
    The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.
    Patent expiration dates:
    • November 11, 2019
      ✓ 
      Patent use: TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
      ✓ 
      Drug product
    • May 11, 2020
      ✓ 
      Pediatric exclusivity
  • Therapeutic formulation for administering tolterodine with controlled release
    Patent 6,770,295
    Issued: August 3, 2004
    Inventor(s): Bo; Kreilgård & Lene; Orup Jacobsen & Ulla; Hoeck & Helle; Kristensen & Torkel; Gren & Lisbeth; Nilvebrant & Anders; Ringberg & Martin; Wikberg & Bengt; Hallén & Birgitta; Olsson & Jan; Strömbom
    Assignee(s): Pharmacia AB
    The present invention is drawn to a method of treating an unstable or overactive urinary bladder by treating the patient with tolterodine or a tolterodine-related compound, or pharmaceutically acceptable salt thereof, with a controlled release formulation that maintains a substantially constant serum level of the active moiety or moieties for at least 24 hours. The present invention is further drawn to a formulation for the method.
    Patent expiration dates:
    • August 26, 2019
      ✓ 
      Patent use: TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
      ✓ 
      Drug product
    • February 26, 2020
      ✓ 
      Pediatric exclusivity
  • Controlled release bead, a method of producing the same and multiple unit formulation comprising it
    Patent 6,911,217
    Issued: June 28, 2005
    Inventor(s): Gren; Torkel & Ringberg; Anders & Wikberg; Martin & Wald; Randy J.
    Assignee(s): Pharmacia AB
    A controlled release bead comprises: (i) a core unit of a substantially water-soluble or water-swellable inert material; (ii) a first layer on the core unit of a substantially water-insoluble polymer; (iii) a second layer covering the first layer and containing an active ingredient; and (iv) a third layer of polymer on the second layer effective for controlled release of the active ingredient, wherein the first layer is adapted to control water penetration into the core. A method of producing the controlled release bead is also disclosed.
    Patent expiration dates:
    • November 11, 2019
      ✓ 
      Patent use: TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
      ✓ 
      Drug product
    • May 11, 2020
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web3)